Benefit of Perindopril Treatment in Persistent Microalbuminuria in Hypertensive Patients with Diabetes Compared to Well

controlled Normotensive Diabetic Patients without Perindopril Treatment

Abstract

To determine the benefit of periondopril, an angiotensin-converting enzyme inhibitor (ACE inhibitor), on early diabetic nephropathy in patients with mild hypertension, we conducted a 1-year follow-up study monitoring blood pressure, HbA_1c, and urinary albumin in 8 patients with mild hypertension who received perindopril treatment, and compared these results to those for 9 well-controlled diabetic patients with normotension and microalbuminuria not receiving perindopril treatment.One year later, all 8 patients receiving perindopril showed improved microalbuminuria, while only 3 of the 9 patients with normotension showed reduced microalbuminuria (P=0.0067).Urinary albumin increased from 71.8±45.3 mg/g·Cr to 96.9±62.7mg/g·Cr (p=0.261) in patients with normotension.In contrast, in patients with mild hypertension receiveing perindopril, urinary albumin decreased from 98.3±57.7 mg/g·Cr to 43.4±30.0 mg/g·Cr (P=0.013). Patients with mild hypertension receiving perindopril showed significantly reduced microalbuminuria compared to normotensive patients not receiving perindopril (P=0.010).